Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
3.70
Nov 10 • 3:59 PM ET Dollar change+0.13 Percentage change(3.64%)
Aftermarket Close
3.74
Aftermarket • 7:30 PM ET Dollar change+0.04 Percentage change(1.08%)
Today, 11:16 AMSionna posts Q3 2026 non-GAAP EPS -$0.72, misses EPS but beats revenue estimates, to advance SION-451 + SION-2222 into AscenSION CF Phase 2 trial in Q1 2027
Index
RUT
Market Cap
167.29M
Enterprise Value
-49.55M
Income
-109.52M
Sales
0.00M
Book/sh
5.32
Cash/sh
4.97
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
59
IPO
Feb 07, 2025
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.70
P/C
0.74
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
13.92
Current Ratio
13.92
Debt/Eq
0.03
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-2.43
EPS next Y
-2.39
EPS next Q
-0.61
EPS this Y
-36.99%
EPS next Y
7.17%
EPS next 5Y
-11.48%
EPS past 3/5Y
-22.66% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-52.03%
Sales Y/Y TTM
-
EPS Q/Q
-57.22%
Sales Q/Q
-
Insider Own
47.89%
Insider Trans
-17.04%
Inst Own
71.46%
Inst Trans
12.39%
ROA
-36.35%
ROE
-38.96%
ROIC
-44.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-2.50%
SMA50
-27.73%
SMA200
-87.15%
Trades
Shs Outstand
45.21M
Shs Float
23.56M
52W High
54.97 -93.27%
52W Low
3.19 15.99%
Volatility
10.59% 8.70%
ATR (14)
0.40
RSI (14)
36.65
Beta
1.26
Rel Volume
0.42
Avg Volume
2.29M
Volume
954,720
Perf Week
1.37%
Perf Month
-21.11%
Perf Quarter
-40.80%
Perf Half Y
-90.96%
Perf YTD
-91.01%
Perf Year
-89.66%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
3.57
Price
3.70
Change %
3.64%
Consensus
Hold
Avg. Price Target
$15.33
Implied Upside
+314.3%
Analysts8incl. previous ratings
Rating Distribution1 Buy · 7 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 10, 2026Upgrade
RY logoRRBC Capital Mkts
Underperform → Sector Perform$5+35.1%
Aug 10, 2026Downgrade
WWedbush
Outperform → Neutral$5+35.1%
Aug 10, 2026Downgrade
SF logoSStifel
Buy → Hold$7+89.2%
Aug 10, 2026Downgrade
RJF logoRRaymond James
Strong Buy → Mkt Perform
Aug 10, 2026Downgrade
GGuggenheim
Buy → Neutral
Aug 10, 2026Downgrade
CCitizens
Mkt Outperform → Mkt Perform
Aug 10, 2026Downgrade
BBTIG Research
Buy → Neutral
May 05, 2026Initiated
WWedbush
Outperform$53+1,332.4%
Feb 24, 2026Initiated
CCitizens
Mkt Outperform$63+1,602.7%
Dec 01, 2025Downgrade
RY logoRRBC Capital Mkts
Sector Perform → Underperform$24+548.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorSep 17 '26Sale6.333,448,81121,835,0183,448,812Sep 21 06:56 PM
RA Capital Healthcare Fund, L.DirectorSep 17 '26Proposed Sale6.333,448,81121,834,318Sep 17 05:10 PM
Thompson Peter A.DirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09 04:47 PM
ORBIMED ADVISORS LLCDirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09 04:44 PM
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Option Exercise6.1110,25062,62810,250Jul 07 04:38 PM
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Sale43.6010,250446,8620Jul 07 04:38 PM
JENNIFER FITZPATRICKOfficerJul 06 '26Proposed Sale43.9910,250450,898Jul 06 04:39 PM
Thompson Peter A.DirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02 04:45 PM
ORBIMED ADVISORS LLCDirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02 04:42 PM
Thompson Peter A.DirectorMay 27 '26Sale44.491014,4932,671,721May 29 09:02 PM
ORBIMED ADVISORS LLCDirectorMay 27 '26Sale44.491014,4932,671,721May 29 08:57 PM
OrbiMed Private Investments VIShareholderMay 29 '26Proposed Sale42.801,082,48046,330,144May 29 06:44 PM
Thompson Peter A.DirectorMay 11 '26Sale46.22184,6398,534,0152,671,822May 11 07:14 PM
Thompson Peter A.DirectorMay 08 '26Sale44.5859,7672,664,4132,856,461May 11 07:14 PM
Thompson Peter A.DirectorMay 07 '26Sale44.6148,5462,165,6372,916,228May 11 07:14 PM
ORBIMED ADVISORS LLCDirectorMay 11 '26Sale46.22184,6398,534,0152,671,822May 11 06:58 PM
ORBIMED ADVISORS LLCDirectorMay 08 '26Sale44.5859,7672,664,4132,856,461May 11 06:58 PM
ORBIMED ADVISORS LLCDirectorMay 07 '26Sale44.6148,5462,165,6372,916,228May 11 06:58 PM
Thompson Peter A.DirectorApr 17 '26Sale44.6852,3972,341,0982,967,722Apr 21 08:42 PM
Thompson Peter A.DirectorApr 18 '26Sale44.522,948131,2452,964,774Apr 21 08:42 PM
ORBIMED ADVISORS LLCDirectorApr 17 '26Sale44.6852,3972,341,0982,967,722Apr 21 08:40 PM
ORBIMED ADVISORS LLCDirectorApr 18 '26Sale44.522,948131,2452,964,774Apr 21 08:40 PM
Thompson Peter A.DirectorApr 15 '26Sale44.64235,86310,528,9243,247,025Apr 16 07:15 PM
Thompson Peter A.DirectorApr 16 '26Sale45.34226,90610,287,9183,020,119Apr 16 07:15 PM
Thompson Peter A.DirectorApr 14 '26Sale44.5147,8142,128,2013,482,888Apr 16 07:15 PM
ORBIMED ADVISORS LLCDirectorApr 15 '26Sale44.64235,86310,528,9243,247,025Apr 16 07:03 PM
ORBIMED ADVISORS LLCDirectorApr 16 '26Sale45.34226,90610,287,9183,020,119Apr 16 07:03 PM
ORBIMED ADVISORS LLCDirectorApr 14 '26Sale44.5147,8142,128,2013,482,888Apr 16 07:03 PM
Fitzpatrick JenniferChief Legal OfficerMar 05 '26Option Exercise6.1110,25062,62810,250Mar 06 06:56 PM
Fitzpatrick JenniferChief Legal OfficerMar 05 '26Sale33.8610,250347,0190Mar 06 06:56 PM
JENNIFER FITZPATRICKOfficerMar 05 '26Proposed Sale34.5710,250354,342Mar 05 04:28 PM
Thompson Peter A.DirectorFeb 03 '26Sale44.5829,0631,295,6293,530,702Feb 04 07:43 PM
Thompson Peter A.DirectorFeb 02 '26Sale44.571,89084,2373,559,765Feb 04 07:43 PM
ORBIMED ADVISORS LLCDirectorFeb 03 '26Sale44.5829,0631,295,6293,530,702Feb 04 07:39 PM
ORBIMED ADVISORS LLCDirectorFeb 02 '26Sale44.571,89084,2373,559,765Feb 04 07:39 PM
TPG GP A, LLC10% OwnerJan 22 '26Sale40.00250,00010,000,0006,494,962Jan 26 05:24 PM
Rise Fund Sling, L.P.StockholderJan 22 '26Proposed Sale41.77195,6678,173,011Jan 22 08:47 PM
Rise Fund Sling II, L.P.StockholderJan 22 '26Proposed Sale41.7754,3332,269,489Jan 22 08:47 PM
ORBIMED ADVISORS LLCDirectorDec 24 '25Sale44.5533,3561,486,0103,561,655Dec 29 08:44 PM
Thompson Peter A.DirectorDec 24 '25Sale44.5533,3561,486,0103,561,655Dec 29 08:42 PM
ORBIMED ADVISORS LLCDirectorDec 17 '25Sale44.5090040,0503,595,986Dec 19 07:29 PM
ORBIMED ADVISORS LLCDirectorDec 19 '25Sale44.4987538,9293,595,011Dec 19 07:29 PM
ORBIMED ADVISORS LLCDirectorDec 18 '25Sale44.491004,4493,595,886Dec 19 07:29 PM
Thompson Peter A.DirectorDec 17 '25Sale44.5090040,0503,595,986Dec 19 07:24 PM
Thompson Peter A.DirectorDec 19 '25Sale44.4987538,9293,595,011Dec 19 07:24 PM
Thompson Peter A.DirectorDec 18 '25Sale44.491004,4493,595,886Dec 19 07:24 PM
Fitzpatrick JenniferChief Legal OfficerDec 05 '25Option Exercise6.1110,25062,62810,250Dec 09 04:57 PM
Fitzpatrick JenniferChief Legal OfficerDec 05 '25Sale40.5210,250415,3300Dec 09 04:57 PM
JENNIFER R FITZPATRICKOfficerDec 05 '25Proposed Sale40.8810,250419,020Dec 05 04:27 PM
ORBIMED ADVISORS LLCDirectorNov 24 '25Sale44.5494,5834,212,7273,610,376Nov 26 06:45 PM
ORBIMED ADVISORS LLCDirectorNov 25 '25Sale44.6011,890530,2943,598,486Nov 26 06:45 PM
ORBIMED ADVISORS LLCDirectorNov 26 '25Sale44.491,60071,1843,596,886Nov 26 06:45 PM
Thompson Peter A.DirectorNov 24 '25Sale44.5494,5834,212,7273,610,376Nov 26 06:41 PM
Thompson Peter A.DirectorNov 25 '25Sale44.6011,890530,2943,598,486Nov 26 06:41 PM
Thompson Peter A.DirectorNov 26 '25Sale44.491,60071,1843,596,886Nov 26 06:41 PM
OrbiMed Private Investments VIShareholderNov 24 '25Proposed Sale44.381,047,77046,500,033Nov 24 08:22 PM
RA CAPITAL MANAGEMENT, L.P.DirectorNov 21 '25Sale39.5025,183994,728159,033Nov 24 05:43 PM
RA CAPITAL MANAGEMENT, L.P.DirectorNov 20 '25Sale40.135,133205,975166,642Nov 24 05:43 PM
RA Capital Healthcare Fund LPDirectorNov 21 '25Proposed Sale43.661,21052,829Nov 21 04:24 PM
RA Capital Nexus Fund III, L.PDirectorNov 21 '25Proposed Sale43.666,440281,170Nov 21 04:21 PM
RA Capital Nexus Fund, L.P.DirectorNov 21 '25Proposed Sale43.669,924433,282Nov 21 04:19 PM
BLACKWELL PARTNERS LLC - SERIEDirectorNov 21 '25Proposed Sale43.667,609332,209Nov 21 04:17 PM
RA Capital Nexus Fund III, L.PDirectorNov 20 '25Proposed Sale38.941,31351,128Nov 20 04:40 PM
RA Capital Nexus Fund, L.P.DirectorNov 20 '25Proposed Sale38.942,02378,776Nov 20 04:35 PM
RA Capital Healthcare Fund LPDirectorNov 20 '25Proposed Sale38.942469,579Nov 20 04:34 PM
BLACKWELL PARTNERS LLC - SERIEDirectorNov 20 '25Proposed Sale38.941,55160,396Nov 20 04:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorNov 17 '25Sale40.5981,9873,328,081184,619Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.DirectorNov 19 '25Sale40.0147,4421,898,173168,193Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.DirectorNov 18 '25Sale39.576,922273,904182,527Nov 19 08:43 PM
RA Capital Healthcare Fund LPDirectorNov 19 '25Proposed Sale39.122,27889,115Nov 19 05:21 PM
BLACKWELL PARTNERS LLC - SERIEDirectorNov 19 '25Proposed Sale38.4114,334550,568Nov 19 05:16 PM
RA Capital Nexus Fund, L.P.DirectorNov 19 '25Proposed Sale38.4118,696718,113Nov 19 05:10 PM
RA Capital Nexus Fund III, L.PDirectorNov 19 '25Proposed Sale38.4112,134466,066Nov 19 05:04 PM
BLACKWELL PARTNERS LLC - SERIEDirectorNov 18 '25Proposed Sale39.042,09281,671Nov 18 05:22 PM
RA Capital Nexus Fund, L.P.DirectorNov 18 '25Proposed Sale39.042,728106,501Nov 18 05:17 PM
RA Capital Nexus Fund III, L.PDirectorNov 18 '25Proposed Sale39.041,77069,100Nov 18 05:09 PM
RA Capital Healthcare Fund LPDirectorNov 18 '25Proposed Sale39.0433212,961Nov 18 04:58 PM
BLACKWELL PARTNERS LLC - SERIEDirectorNov 17 '25Proposed Sale39.9324,772989,146Nov 17 05:12 PM
RA Capital Nexus Fund, L.P.DirectorNov 17 '25Proposed Sale39.9332,3101,290,138Nov 17 05:04 PM
RA Capital Nexus Fund III, L.PDirectorNov 17 '25Proposed Sale39.9320,969837,292Nov 17 04:56 PM
RA Capital Healthcare Fund LPDirectorNov 17 '25Proposed Sale39.933,936157,164Nov 17 04:46 PM
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.
PresidentMr. Michael Cloonan M.B.A.
CFO & Chief Business OfficerMs. Elena H. Ridloff C.F.A.
Co-Founder & Senior VP of Discovery ResearchDr. Greg Hurlbut Ph.D.
Co-founderDr. Mark Munson Ph.D.
Vice President of Information & TechnologyMr. Andy Chu